UNASSIGNED: Background Malaria treatment is recommended for @entity1 with suspected @entity2598 ( @entity2598 ) in West Africa, whether systeomatically or based on confirmed @entity311 diagnosis. At the Ebola treatment center in Foya, Lofa County, Liberia, the supply of @entity15280 - @entity15281 , a first-line antimalarial combination drug, ran out for a 12-day period in August 2014. During this time, @entity1 received the combination drug @entity506 - @entity16944 ; @entity16944 is a compound with anti-Ebola virus activity in vitro. No other obvious change in the care of @entity1 occurred during this period. Methods We fit unadjusted and adjusted regression models to standardized @entity1 -level data to estimate the risk ratio for @entity204 among @entity1 with confirmed @entity2598 who were prescribed @entity506 - @entity16944 ( @entity506 - @entity16944 group), as compared with those who were prescribed @entity15280 - @entity15281 ( @entity15280 - @entity15281 group) and those who were not prescribed any antimalarial drug (no-antimalarial group). Results Between June 5 and October 24, 2014, a total of 382 @entity1 with confirmed @entity2598 were admitted to the Ebola treatment center in Foya. At admission, 194 @entity1 were prescribed @entity15280 - @entity15281 and 71 were prescribed @entity506 - @entity16944 . The characteristics of the @entity1 in the @entity506 - @entity16944 group were similar to those in the @entity15280 - @entity15281 group and those in the no-antimalarial group. A total of 125 of the 194 @entity1 in the @entity15280 - @entity15281 group (64.4%) died, as compared with 36 of the 71 @entity1 in the @entity506 - @entity16944 group (50.7%). In adjusted analyses, the @entity506 - @entity16944 group had a 31% lower risk of @entity204 than the @entity15280 - @entity15281 group (risk ratio, 0.69; 95% confidence interval, 0.54 to 0.89), with a stronger effect observed among @entity1 without @entity311 . Conclusions @entity1 who were prescribed @entity506 - @entity16944 had a lower risk of @entity204 from @entity2598 than did @entity1 who were prescribed @entity15280 - @entity15281 . However, our analyses cannot exclude the possibility that @entity15280 - @entity15281 is associated with an increased risk of @entity204 or that the use of @entity506 - @entity16944 was associated with unmeasured @entity1 characteristics that directly altered the risk of @entity204 .

Effect of XXXX - @entity16944 on Mortality Related to @entity2598 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity15281 :: ('MESH:C102070', 'Chemical') :: ['lumefantrine'] @entity2598 :: ('MESH:D019142', 'Disease') :: ['Ebola virus disease', 'EVD'] @entity16944 :: ('MESH:D000655', 'Chemical') :: ['amodiaquine'] @entity15280 :: ('MESH:C032942', 'Chemical') :: ['artemether'] @entity506 :: ('MESH:C039726', 'Chemical') :: ['artesunate'] @entity311 :: ('MESH:D008288', 'Disease') :: ['malaria'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity506 :: (MESH:C039726,Chemical) :: ['Artesunate']
